Answers are grounded in this paper and cite their sources.
Ankylosing spondylitis (AS) is a chronic, inflammatory, rheumatic disease involving primarily the spine and sacroiliac joints.It is a prototype of spondyloarthritis (SpA) group diseases and its prevalence in Turkey has been reported as 0.49% (1).It is encountered in mostly young adults and in 80% of the cases symptoms appear before 30 years of age (2).Studies have revealed that the quality of life is reduced and the risk of disability and mortality is increased in patients with AS (3,4).It has been reported that the direct (due to health expenses) and indirect (as a result of workforce loss) economic losses associated with the disease are similar to those of rheumatoid arthritis (RA) in the long term (5).Management of AS consists of pharmacological and nonpharmacological treatment modalities (6-11).The pharmacological treatment options are limited; however, with the recent introduction of biological drugs, remarkable improvements have been reported in this field.In general, the treatment targets include control of symptoms and inflammation (pain, stiffness, and joint swelling), preservation/normalization of physical function, prevention of progressive structural damage and disabilities, and eventually maximizing the longterm health-related quality of life (6,11).The aim of this review article is to present an updated overview of the pharmacologic treatment of AS, as defined by the modified New York criteria (Table 1) (12).Nonpharmacological treatment modalities including physiotherapy and exercise are only briefly mentioned and surgical treatment is not discussed. Nonpharmacological treatment approaches: physiotherapy and exerciseThe nonpharmacological treatment for AS comprises patient training and regular exercise.Pharmacological treatment and nonpharmacological treatment approaches complement each other.Physiotherapy and exercise for the treatment of AS are also cost-effective (13).A recent Cochrane article summarized the available scientific evidence on the effectiveness of physiotherapy interventions in the management of AS ( 14).Personal home exercising and training, when compared to AS patients without such interventions, lead to significant improvement in some spinal mobility parameters (finger tips-to-floor distance); however, they have no effect on disease activity, pain, stiffness, and global patient evaluation (14).Studies comparing group physiotherapy programs applied with a supervisor with personal home exercise programs showed that there were no differences among groups in regard to pain, stiffness, and function; however, some spinal mobility parameters (Schober's distance) and patient global Abstract: Ankylosing spondylitis is a chronic, inflammatory, rheumatic disease that can reduce the quality of life and increase the risk of disability and mortality.It also causes direct and indirect economic losses due to health expenses and as a result of workforce loss.Management of this disease consists of pharmacological and nonpharmacological modalities.Until recently, pharmacological treatment options have been very limited.However, development of novel biological drugs revolutionized the management of this disease.The aim of this review article is to present an updated overview of the pharmacologic treatment of ankylosing spondylitis.Nonpharmacological treatment modalities including physiotherapy and exercise are only briefly mentioned and surgical treatment is not discussed.
No takes yet. Share an insight, caveat, or question.
Sarı et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: